THE LONG-TERM OBJECTIVE IS TO PREPARE AN EFFECTIVE LIPOSOME ENCAPSULATED REAGENT WHICH WILL BE PREFERENTIALLY TARGETED TO LIVER MACROPHAGES RESULTING IN MACROPHAGE ACTIVATION FOR THE THERAPY OF METASTATIC HEPATIC DISEASE.

THE LONG-TERM OBJECTIVE IS TO PREPARE AN EFFECTIVE LIPOSOME ENCAPSULATED REAGENT WHICH WILL BE PREFERENTIALLY TARGETED TO LIVER MACROPHAGES RESULTING IN MACROPHAGE ACTIVATION FOR THE THERAPY OF METASTATIC HEPATIC DISEASE. THE SPECIFIC AIMS ARE: 1.TO PRODUCE A LIPOPHILIC DERIVATIVE OF THE MYCOBACTERIAL CELL WALL AND INCORPORATE THAT IN LIPOSOMES DESIGNED TO BE PREFERENTIALLY TAKEN UP 2.TO DETERMINE THE TOXICITY OF THE REAGENT; 4.TO DETERMINE THE EFFECTS ON HEPATIC METASTASIS IN SEVERAL ANIMAL MODELS; AND 5.TO DETERMINE THE TOXICITY AND IMMUNOLOGICAL EFFECTS IN PHASE I AND II CLINICAL TRIALS. COMPLETION OF THIS PROJECT WILL IDENTIFY THE POTENTIAL OF THE REAGENT AND POTENTIAL COMMERCIAL VALUE. FURTHER PHASE I OR II TESTING, IF INDICATED, MAY BE DONE UNDER NCI AUSPICES, AS PART OF AN AGREEMENT WITH A PHARMACEUTICAL COMPANY OR USING VENTURE CAPITAL.